This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Why GE HealthCare Technologies (GEHC) is a Top Value Stock for the Long-Term
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Reasons to Retain GE HealthCare Stock in Your Portfolio Now
by Zacks Equity Research
GEHC's continued focus on innovations, acquisitions and partnerships raises optimism about the stock.
TransMedics Stock Plunges 57.5% in Three Months: What's Next?
by Debanjana Dey
TMDX is enhancing its current focus on making meaningful progress across each of its growth initiatives. However, macro challenges are likely to hurt its performance.
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
GEHC Stock May Gain Following the Launches of Aurora and Clarify DL
by Zacks Equity Research
GE HealthCare announces that Aurora will expand the range of CT procedures and Clarify DL will enhance SPECT image quality.
GEHC Stock May Gain From Potential FDA Clearance for CleaRecon DL
by Zacks Equity Research
GE HealthCare announces the FDA submission of its CleaRecon DL technology to improve CBCT images.
RDNT Stock Up Following the New Tie-Up to Leverage Radiology AI
by Zacks Equity Research
RadNet's latest collaboration aims to create an AI control system for image interpretation to ensure AI scalability, performance monitoring and safety.
GEHC Stock May Gain Following the Launch of Sonic DL for 3D Imaging
by Zacks Equity Research
GE HealthCare announces the new Sonic DL for 3D, which will reduce scan times and provide faster, high-quality imaging for the majority of MR scans.
GEHC Stock Up Following New Tie-Up to Boost Cancer Research and Care
by Zacks Equity Research
The latest collaboration aims to provide new opportunities to improve cancer diagnosis using GE HealthCare's technology and enhance clinical workflow.
GEHC Stock May Gain Following the Launch of Pristina Via System
by Zacks Equity Research
GE HealthCare announces the Pristina Via mammography system, which will help minimize repetitive tasks and streamline workflows for mammography technologists.
GEHC Stock May Gain on Its Enhanced OEC 3D Mobile CBCT C-Arm Portfolio
by Zacks Equity Research
GE HealthCare announces the latest application additions to its OEC 3D mobile CBCT C-arm portfolio to improve clinician workflow and visualization during endoscopic bronchoscopy procedures.
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
GEHC Stock Likely to Gain on Portrait Mobile Solution's Prospects
by Zacks Equity Research
GE HealthCare's Portrait Mobile solution will provide continuous monitoring in post-surgery settings. It will also deliver informative alarms, advancing patient care while alleviating the burdens faced by clinicians.
GE HealthCare and DeepHealth Collaborate to Advance AI in Imaging
by Zacks Equity Research
GEHC and DeepHealth collaborate to develop AI-based imaging tools that can streamline workflow and help manage large imaging volumes without compromising diagnostic accuracy.
GEHC Stock Falls Despite FDA Clearance for SIGNA MAGNUS MRI System
by Zacks Equity Research
GE Healthcare receives FDA clearance for its head-only SIGNA MAGNUS 3.0T MRI System.
Here's Why GE HealthCare Technologies (GEHC) is a Strong Value Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
GE HealthCare Q3 Earnings Beat Estimates, Sales Meet, Net Margin Up
by Zacks Equity Research
GEHC's third-quarter results witness declining segmental revenues in imaging and ultrasound, offset by strong Pharmaceutical Diagnostics performance. The bottom line improves on better pricing.
GE HealthCare (GEHC) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
While the top- and bottom-line numbers for GE HealthCare (GEHC) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
GE HealthCare Technologies (GEHC) Tops Q3 Earnings Estimates
by Zacks Equity Research
GE HealthCare (GEHC) delivered earnings and revenue surprises of 7.55% and 0.02%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
DH vs. GEHC: Which Stock Is the Better Value Option?
by Zacks Equity Research
DH vs. GEHC: Which Stock Is the Better Value Option?
Will Amazon's Q3 Earnings Benefit From Consistent Momentum in AWS?
by Zacks Equity Research
AMZN's third-quarter results are expected to reflect significant gains from AWS momentum, driven by growing generative AI capabilities.
Lower Volume Likely to Hurt GE HealthCare's Q3 Earnings
by Zacks Equity Research
GEHC's third-quarter results are likely to witness declining segmental revenues in imaging, ultrasound and patient care. The bottom-line figure may reflect better pricing.
Hims & Hers Health, Inc. (HIMS) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Hims & Hers Health (HIMS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Unveiling GE HealthCare (GEHC) Q3 Outlook: Wall Street Estimates for Key Metrics
by Zacks Equity Research
Besides Wall Street's top -and-bottom-line estimates for GE HealthCare (GEHC), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended September 2024.
GEHC Stock Declines Despite the Unveiling of CareIntellect Application
by Zacks Equity Research
GE Healthcare announces CareIntellect for Oncology to provide multi-modal patient data from disparate systems into a single view using generative AI.